Keros Board Announces $5M Stock Repurchase
Keros Therapeutics authorized a $5 million share repurchase program following a $20 million milestone payment from Takeda. The board grants management flexibility for open-market stock buybacks.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day